A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

Also called NCT05515393

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05515393
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05515393. Randomized; triple masking; primary purpose treatment. Start 2022-09-24 (actual); primary completion 2023-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Acronym
XY03-EA
Condition
Acute Ischemic Stroke
Intervention (Drug)
XY03-EA
Intervention (Drug)
XY03-EA Placebo
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd (class: industry)
Collaborator
First Affiliated Hospital, Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct05515393
Content hash
90b695ab9185862d8ee4ac27c03961cf3fc0c335e0670e5ef1cc830895f08e99